Medicenna Therapeutics Corp (MDNAF)

$0.59 -0.01 (-2.15%)
Market Cap 50.05M
Revenue (ttm) 0.00
Net Income (ttm) -8.48M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 51,900
Avg Vol 128,934
Day's Range N/A - N/A
Shares Out 83.41M
Stochastic %K 7%
Beta 1.81
Analysts Strong Sell
Price Target $2.96

Company Profile

Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, a long-acting interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; MDNA209, an IL-2/IL-15...

Industry: Biotechnology
Sector: Healthcare
Phone: 416 648 5555
Address:
2 Bloor Street West, Suite 903 7th Floor, Toronto, Canada
Lytnup
Lytnup Feb. 15 at 4:01 PM
$MDNAF Some data points to absorb about the (2) recent additions to the BOD https://www.jcclark.com/team/ https://angelosgeorgakis.com/#testimonials Lingering question for me that I hope I can find an answer to in the next few months: in a cash-strapped situation, why would the company bring a 2nd compound to the clinic in addition to pursuing a registrational / pivotal trial on MDNA11?
0 · Reply
Gobblin
Gobblin Feb. 13 at 5:25 PM
$MDNAF My AI buddy re addition of new board members. Adding capital markets + inflection-point directors suggests: They are preparing for: • Either structured partnership • Or maximizing valuation into next data release Companies don’t upgrade boards like this just to drift.
0 · Reply
Biosectors
Biosectors Feb. 13 at 2:31 PM
$MDNAF Good morning and good luck If Merck doesn’t make a move in the next few days or up until conference the platform will be up for grabs by big guys is my gut feeling. This is the best news under the situation and circumstances for longs Medicenna is the only superkine best in its class and best data with keytruda combo or pd1 all others IL have failed Go figure why this news alters the whole paradigm here Have a nice Friday and long weekend all longs I am praying and hoping good news waiting since early 2022 with lot of patience
0 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Feb. 13 at 2:26 PM
$MDNAF 3d Q https://ir.medicenna.com/news-releases/news-release-details/medicenna-therapeutics-reports-third-quarter-fiscal-2026/
0 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Feb. 13 at 12:55 PM
$MDNAF Anyone’s thoughts on the new Board additions? Buyout prep or dilution !?! https://ir.medicenna.com/news-releases/news-release-details/medicenna-announces-changes-board-composition/
2 · Reply
Lytnup
Lytnup Feb. 11 at 5:59 PM
$MDNAF While we wait: Q3 numbers have historically been released this week; and David has published another article that has some interesting information on some trending items. https://open.substack.com/pub/davidbakke/p/pulse-check-update?r=10wt7d&utm_medium=ios
0 · Reply
Lytnup
Lytnup Feb. 10 at 6:24 PM
$MDNAF In the “For What It’s Worth” department - new 52-week low set.
2 · Reply
_Osmium
_Osmium Feb. 5 at 3:14 PM
$MDNAF A longtime holders sold and I can relate. He brought up a good point regarding MDNA11 vs THOR 707 so I thought I put this here. I'm surprised David (substack) didn't deep dive this more: THOR-707 (Sanofi) ✔ First-generation engineered IL-2 without IL-2Rα binding ✔ Showed expected immune bias in early trials ❌ Lower potency and clinical efficacy than hoped; program discontinued MDNA11 ✔ Next-generation IL-2 superkine with enhanced IL-2Rβ affinity and albumin fusion ✔ Demonstrates promising clinical responses and durable immune cell expansion ✔ Favorable safety and dosing profiles ✔ Still actively in Phase 1/2 development Bottom line: Both drugs share a common immuno-oncology strategy — leverage IL-2 signaling to stimulate anti-tumor immunity without triggering regulatory T cells and toxicities — but MDNA11’s enhanced receptor engagement and extended half-life appear to translate into stronger, more durable clinical activity compared with THOR-707’s earlier approach.
0 · Reply
Biosectors
Biosectors Feb. 4 at 11:03 PM
$MDNAF Sorry to hear the sequence of events that prompted you to exit this quality science and future of IL 2 space that Medicenna is on the verge of adding a huge value based on the recent findings and the internal external read out plus MDNA55 with phase 3 ready. I am hoping the conference next week in Boston will bring a lot more to the table and big guys like Merck or BMS may fund to carry on the path laid out. Wish you good luck and wish others here for a nice return in the months ahead. I am holding this entire year and then take a call. I loaded more in anticipation of some exciting data read out on 17-19 so it catches big guys attention. RA capital invested at around 1.45$ it’s at 65cents now, RA is a biotech shark they don’t invest without the potential and they exit with a profit hence I will hold till this whatever happens it’s ok.
2 · Reply
Spartrap
Spartrap Feb. 4 at 4:38 PM
$MDNAF fully out now. I wish you well longs. Dilution risk is getting too high now and I loathe the recent licensing of a bullshitting platform & general lower quality of scientific publications lately. That indicates a shift toward retail that rarely works out for investors. Toxic financing with warrant are sure to follow. If I had to do a forensic of my failed investment here, I'd say I downplayed way too much the risk induced by the co leaving the Nasdaq. The visibility and cred suffered immensely and it became extremely challenging for even a competent CEO to convey their message to the right ears. I came hot on the heels of the RA capital investment and it took me more than a year to understand RA were in fact simply betting on the success of Sanofi's THOR-707. When Sanofi abruptly discontinued their trials in October 24, the bet failed. I still see potential for 113 but the compound is too early. I don't like the probability of a deal there. It could happen though
2 · Reply
Latest News on MDNAF
No data available.
Lytnup
Lytnup Feb. 15 at 4:01 PM
$MDNAF Some data points to absorb about the (2) recent additions to the BOD https://www.jcclark.com/team/ https://angelosgeorgakis.com/#testimonials Lingering question for me that I hope I can find an answer to in the next few months: in a cash-strapped situation, why would the company bring a 2nd compound to the clinic in addition to pursuing a registrational / pivotal trial on MDNA11?
0 · Reply
Gobblin
Gobblin Feb. 13 at 5:25 PM
$MDNAF My AI buddy re addition of new board members. Adding capital markets + inflection-point directors suggests: They are preparing for: • Either structured partnership • Or maximizing valuation into next data release Companies don’t upgrade boards like this just to drift.
0 · Reply
Biosectors
Biosectors Feb. 13 at 2:31 PM
$MDNAF Good morning and good luck If Merck doesn’t make a move in the next few days or up until conference the platform will be up for grabs by big guys is my gut feeling. This is the best news under the situation and circumstances for longs Medicenna is the only superkine best in its class and best data with keytruda combo or pd1 all others IL have failed Go figure why this news alters the whole paradigm here Have a nice Friday and long weekend all longs I am praying and hoping good news waiting since early 2022 with lot of patience
0 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Feb. 13 at 2:26 PM
$MDNAF 3d Q https://ir.medicenna.com/news-releases/news-release-details/medicenna-therapeutics-reports-third-quarter-fiscal-2026/
0 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Feb. 13 at 12:55 PM
$MDNAF Anyone’s thoughts on the new Board additions? Buyout prep or dilution !?! https://ir.medicenna.com/news-releases/news-release-details/medicenna-announces-changes-board-composition/
2 · Reply
Lytnup
Lytnup Feb. 11 at 5:59 PM
$MDNAF While we wait: Q3 numbers have historically been released this week; and David has published another article that has some interesting information on some trending items. https://open.substack.com/pub/davidbakke/p/pulse-check-update?r=10wt7d&utm_medium=ios
0 · Reply
Lytnup
Lytnup Feb. 10 at 6:24 PM
$MDNAF In the “For What It’s Worth” department - new 52-week low set.
2 · Reply
_Osmium
_Osmium Feb. 5 at 3:14 PM
$MDNAF A longtime holders sold and I can relate. He brought up a good point regarding MDNA11 vs THOR 707 so I thought I put this here. I'm surprised David (substack) didn't deep dive this more: THOR-707 (Sanofi) ✔ First-generation engineered IL-2 without IL-2Rα binding ✔ Showed expected immune bias in early trials ❌ Lower potency and clinical efficacy than hoped; program discontinued MDNA11 ✔ Next-generation IL-2 superkine with enhanced IL-2Rβ affinity and albumin fusion ✔ Demonstrates promising clinical responses and durable immune cell expansion ✔ Favorable safety and dosing profiles ✔ Still actively in Phase 1/2 development Bottom line: Both drugs share a common immuno-oncology strategy — leverage IL-2 signaling to stimulate anti-tumor immunity without triggering regulatory T cells and toxicities — but MDNA11’s enhanced receptor engagement and extended half-life appear to translate into stronger, more durable clinical activity compared with THOR-707’s earlier approach.
0 · Reply
Biosectors
Biosectors Feb. 4 at 11:03 PM
$MDNAF Sorry to hear the sequence of events that prompted you to exit this quality science and future of IL 2 space that Medicenna is on the verge of adding a huge value based on the recent findings and the internal external read out plus MDNA55 with phase 3 ready. I am hoping the conference next week in Boston will bring a lot more to the table and big guys like Merck or BMS may fund to carry on the path laid out. Wish you good luck and wish others here for a nice return in the months ahead. I am holding this entire year and then take a call. I loaded more in anticipation of some exciting data read out on 17-19 so it catches big guys attention. RA capital invested at around 1.45$ it’s at 65cents now, RA is a biotech shark they don’t invest without the potential and they exit with a profit hence I will hold till this whatever happens it’s ok.
2 · Reply
Spartrap
Spartrap Feb. 4 at 4:38 PM
$MDNAF fully out now. I wish you well longs. Dilution risk is getting too high now and I loathe the recent licensing of a bullshitting platform & general lower quality of scientific publications lately. That indicates a shift toward retail that rarely works out for investors. Toxic financing with warrant are sure to follow. If I had to do a forensic of my failed investment here, I'd say I downplayed way too much the risk induced by the co leaving the Nasdaq. The visibility and cred suffered immensely and it became extremely challenging for even a competent CEO to convey their message to the right ears. I came hot on the heels of the RA capital investment and it took me more than a year to understand RA were in fact simply betting on the success of Sanofi's THOR-707. When Sanofi abruptly discontinued their trials in October 24, the bet failed. I still see potential for 113 but the compound is too early. I don't like the probability of a deal there. It could happen though
2 · Reply
BigJon123
BigJon123 Feb. 1 at 7:04 PM
$MDNAF looking at David and PRISM-11’s licensing with MDNAF and what it means about his data - if MDNA is willing to pay money to make use of PRISM, is it because they agree with what David has published so far? Their internal data is matching his publishing (ie, PRISM has been correct)? If that is the case and PRISM has been right so far, the outlook is bright for bizaxofusp, MDNA 11 and 113!
2 · Reply
AuriniaBeach
AuriniaBeach Jan. 29 at 9:00 PM
$MDNAF New PRISM-11 post, announcing that David has entered into a professional licensing and collaboration agreement with Medicenna Therapeutics. https://davidbakke.substack.com/p/a-note-on-prism-11-medicenna-and
1 · Reply
Lytnup
Lytnup Jan. 25 at 6:14 PM
$MDNAF Sorry if it’s been posted already - but latest corporate presentation deck for January 2026 is uploaded @ the company website. 50 pages - some kind of record!!! https://ir.medicenna.com/static-files/c4bd4892-7ceb-4d59-b061-77ea834ec278
1 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Jan. 24 at 7:42 PM
$MDNAF For what it’s worth, Zack’s yesterday changed their rating…from a hold rating to a strong-buy rating
2 · Reply
BigJon123
BigJon123 Jan. 22 at 10:36 PM
$MDNAF maybe someone knows something we don’t! Good news on the way?
0 · Reply
Vikingess
Vikingess Jan. 22 at 6:55 PM
$MDNAF What did I miss?
0 · Reply
Dipper2013
Dipper2013 Jan. 22 at 4:50 PM
$MDNAF I think we need bad news to get it to go up...🤣
0 · Reply
Biosectors
Biosectors Jan. 20 at 11:39 PM
$MDNAF Let’s hope some movement in volume and price next week up to conference week. Praying a buy out indication before or after the conference presentation. Take a look at OCUL data due soon a buy out candidate right now 11 plus I am expecting 28 to 35 range offer. Similarly URGN it went to 30 but back to 20 now and a good shot of a buy out 35 to 45 range but no timeline it’s derisked asset generating revenue. SLS another candidate with potential CHRS another one still struggling but expect to be bought out in 2027
0 · Reply
Witzorwitzout1
Witzorwitzout1 Jan. 16 at 11:29 PM
$MDNAF Medicenna (US OTC: MDNAF | CAD: MDNA) long update Medicenna released their 2026 outlook yesterday morning and I want to highlight something important: MDNA11 doesn’t need Keytruda to work. The headline numbers, 50% objective response rate in expansion cohorts, 42% in patients who already failed checkpoint inhibitors, those are monotherapy results. No Keytruda. No Opdivo. Just MDNA11 alone. Think about that. These are patients who tried the blockbuster immunotherapies and they stopped working. MDNA11 is rescuing responses where checkpoints have failed. That’s a big deal. Why this matters for the investment thesis: There are now multiple paths to value here. 1.Monotherapy salvage: Patient fails Keytruda, give MDNA11 alone. This is the registrational path they’re planning for melanoma. 2.Combination play Pair MDNA11 with Keytruda upfront to expand the responder population from ~30% to potentially 40-50%. 3.Neoadjuvant (NEO-CYT) MDNA11 + checkpoint before surgery in earlier-stage melanoma.
1 · Reply
BigJon123
BigJon123 Jan. 16 at 6:52 PM
$MDNAF i bought more before these presentations came out - there is too much potential here IMO. The biggest hurdle (and a major one) is the funding for their plans but I am hopeful that FM can rub big pharma the right way. Interestingly, they’ve dropped the MDNA55 title and have reverted back to bizaxofusp - to me this is a sign they’re pivoting their plans for the drug which the slide deck confirms. Also interesting timing - JP Morgan conference with FM talking to the big wigs and now this latest commercial update drops? I am cautiously excited.
1 · Reply
Dipper2013
Dipper2013 Jan. 16 at 3:10 PM
$MDNAF ..and there we have it...please no more good news..it's killing the stock price🤣
1 · Reply
Dipper2013
Dipper2013 Jan. 16 at 1:46 PM
$MDNAF all I see is a stock that has great news drop 50%>I'd hate to see what happens with bad news
0 · Reply